Decline in the prevalence of neural tube defects following folic acid fortification and its cost-benefit in South Africa. by Abdul-Rauf Sayed et al.
Decline in the Prevalence of Neural Tube Defects
Following Folic Acid Fortification and Its
Cost-Benefit in South Africa
Abdul-Rauf Sayed,1 David Bourne,1* Robert Pattinson,2 Jo Nixon,1 and Bertram Henderson3
1School of Public Health and Family Medicine, University of Cape Town, South Africa
2Medical Research Council, Maternal and Infant Health Care Strategies Research Unit, Department of Obstetrics and Gynaecology,
University of Pretoria, South Africa
3Division of Human Genetics, University of the Free State, South Africa
Received 16 August 2007; Revised 14 November 2007; Accepted 6 December 2007
BACKGROUND: In October 2003 South Africa embarked on a program of folic acid fortification of staple
foods. We measured the change in prevalence of NTDs before and after fortification and assessed the cost
benefit of this primary health care intervention. METHODS: Since the beginning of 2002 an ecological study
was conducted among 12 public hospitals in four provinces of South Africa. NTDs as well as other birth
defect rates were reported before and after fortification. Mortality data were also collected from two inde-
pendent sources. RESULTS: This study shows a significant decline in the prevalence of NTDs following folic
acid fortification in South Africa. A decline of 30.5% was observed, from 1.41 to 0.98 per 1,000 births (RR 5
0.69; 95% CI: 0.49–0.98; p 5 .0379). The cost benefit ratio in averting NTDs was 46 to 1. Spina bifida showed
a significant decline of 41.6% compared to 10.9% for anencephaly. Additionally, oro-facial clefts showed no
significant decline (5.7%). An independent perinatal mortality surveillance system also shows a significant
decline (65.9%) in NTD perinatal deaths, and in NTD infant mortality (38.8%). CONCLUSIONS: The decrease
in NTD rates postfortification is consistent with decreases observed in other countries that have fortified
their food supplies. This is the first time this has been observed in a predominantly African population. The
economic benefit flowing from the prevention of NTDs greatly exceeds the costs of implementing folic acid
fortification. Birth Defects Research (Part A) 82:211–216, 2008.  2008 Wiley-Liss, Inc.
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INTRODUCTION
NTDs are relatively common birth defects. The prefor-
tification estimates of the prevalence vary in South
Africa. In general, lower prevalences are found in urban
regions such as Cape Town (1.3/1,000 births) (Bucci-
mazza et al., 1994), Pretoria (0.99/1,000 births) (Delport
et al., 1995), and Johannesburg (1.18/1,000 births) (Krom-
berg et al., 1982). Higher rates are reported in rural areas
in the Limpopo Province (3.5/1,000 births) (Venter et al.,
1995), and an extremely high NTD prevalence has been
found in rural Transkei districts in the Eastern Cape
Province (6.1/1,000 births) (Ncayiyana, 1986). An earlier
mainly urban based surveillance system reported a prev-
alence of 1.2/1,000 births for the years 1994–2003 (Inter-
national Clearinghouse for Birth Defects Surveillance and
Research, 2005). Christianson et al. (2006) gave an esti-
mate for the country as a whole as 2.5/1,000 births.
Experimental and epidemiological evidence has shown
that periconceptional dietary supplementation with folic
acid can substantially decrease the prevalence of NTDs
(MRC, 1991; Ceizel et al., 1992; Lumley et al., 2001). In
October 2003, South Africa embarked on a National Food
Fortification Program to address micronutrient deficien-
cies in the population. The recommendations to do this
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had been published as long ago as 1978 (Metz et al.,
1978). Micronutrients added to staple foods such as
maize meal and bread flour include: folic acid, vitamin
A, thiamine, pyridoxine iron, and zinc. The Department
of Health (2003) has set the level of fortification for folic
acid in wheat flour at 1.5 mg/kg and in maize meal at
2.21 mg/kg. Maize meal and bread are among the most
widely consumed foods in South Africa. The milling
industry is highly concentrated in South Africa, with 22
large-scale maize millers accounting for approximately
85% of all maize meal produced in the country. Seven-
teen mills produce about 95% of all bread and cake flour
(Department of Agriculture, 2006). These large millers in-
dependently test their products for the correct addition
of micronutrients. A rapid rollout of fortified products
accordingly took place, at approximately 90% coverage.
The cost of fortification is borne by the industry.
The South African Department of Health designated
four birth defects as priorities to be monitored: NTDs;
cleft lip, cleft palate, or both; Down syndrome; and
oculo-cutaneous albinism. The aim of this study was to
establish baseline, prefortification prevalence rates and
postfortification prevalence rates of NTDs and the three
other priority birth defects (non-NTDs) among newborns
to determine whether food fortification influences NTD
prevalence.
METHODS
Since the beginning of 2002 we have been conducting
hospital based surveillance of NTDs (anencephaly, spina
bifida, and encephalocoele), cleft lip, cleft palate, or both,
Down syndrome, and oculo-cutaneous albinism in vari-
ous provinces of South Africa. In each sentinel site,
appropriate health care workers received training in clini-
cal recognition of the priority birth defects by a medical
geneticist. Information on cases was extracted from hos-
pital records and forwarded on a standardized notifica-
tion form to the surveillance team. In this study 12 public
hospitals in four provinces served as sentinel sites, as
reporting from the other sites was inconsistent/incom-
plete for the entire study period. The participating sites
reported the priority birth defects consistently at monthly
periods both pre- and postfortification. NTD prevalence
rates were established among live- and stillbirths during
the period of prefortification (January 2003–June 2004)
and the postfortification period (October 2004–June 2005).
A 3 month intermediate period, July–September 2004,
was excluded so that the pre and post phases could be
clearly separated. The prefortification period included an
allowance of 9 months for gestation following the intro-
duction of fortification, such that none of these births
could have been exposed to fortified foods in the peri-
conceptional period. The denominator birth data during
the study period averaged 53,000 births per annum. The
birth population was in excess of 90% African.
Two additional independent sources of mortality data
were also used to investigate changes in NTD rates.
Data Analysis
Observed prevalence rates with 95% CIs were based
on the Poisson distribution with normal approximation.
Pre- and postfortification rates were compared using risk
ratio (RR) analysis to measure the protective effect of
folic acid fortification. We also calculated the ratio of the
prevalence of NTDs to other priority birth defects in each
time period. If reporting efficiency fell over the study pe-
riod, then an observed drop in the prevalence rates of all
defects would be in part an artifact, but we would expect
the ratio of NTDs to the other defects to remain the same
in the two time periods. The ratio is open to two possible
biases: (a) that because it was known that there was an
interest in NTDs and fortification, NTDs would be pref-
erentially reported; and/or (b) that one or more of the
other birth defects (such as oro-facial clefts) also had a
reduction as a result of fortification. In either event the
bias is conservative, leading to a lower reported decline
than is actually the case.
RESULTS
Table 1 shows a comparison of pre- and postfortifica-
tion prevalence rates. There was a significant decline of
30.5% in the prevalence of NTDs, from 1.41 to 0.98 per
1,000 births (RR 5 0.69; 95% CI: 0.49–0.98; p 5 .0379),
Table 1
Comparison of Pre- and Postfortification Rates of NTD and Non-NTD Birth Defects
Province
Prefortification January 2003 to June 2004 Postfortification October 2004 to June 2005
NTD cases Births Rate/1,000 NTD cases Births Rate/1,000
Eastern Cape 46 21,851 2.11 17 13,482 1.26
KwaZulu Natal 40 37,997 1.05 17 21,791 0.78
Mpumalanga 9 6,604 1.36 4 3,932 1.02
Free State 17 13,135 1.29 7 6,816 1.03
Total 112 79,587 1.41 45 46,021 0.98
95% CI: 95% CI:
1.15–1.67 0.69–1.26
Province Prefortification Postfortification
Non-NTD Births Rate/1,000 Non-NTD Births Rate/1,000
Eastern Cape 28 21,851 1.28 11 13,482 0.82
KwaZulu Natal 42 37,997 1.11 25 21,791 1.15
Mpumalanga 4 6,604 0.61 6 3,932 1.53
Free State 19 13,135 1.45 10 6,816 1.47
Total 93 79,587 1.17 52 46,021 1.13
95% CI: 95% CI:
0.93–1.41 0.82–1.44
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whereas the rates of the other birth defects combined did
not change significantly (RR 5 0.97; 95% CI: 0.69–1.36;
p 5 .8460). The ratio of NTDs to other non-NTD defects
combined was 1.2 in the pre-, and 0.9 in the postfortifica-
tion period, a 28.1% reduction.
Table 2 compares the pre- and postfortification rates of
specific NTD conditions (anencephaly and spina bifida)
and oro-facial clefts. Spina bifida shows the highest sig-
nificant decline of 41.6% (RR 5 0.58; 95% CI: 0.37–0.92; p
5 .0187). The decline for anencephaly was only 10.9%
(RR 5 0.89; 95% CI: 0.50–1.60; p 5 .6985). Oro-facial clefts
showed a nonsignificant decline (5.7%) (RR 5 0.94; 95%
CI: 0.53–1.68; p 5 .8420).
A linear relationship between prefortification NTD
prevalence rates and the reduction in those rates follow-
ing fortification was observed in Canada (De Wals et al.,
2007). A similar phenomenon was observed between
provinces in this study (r2 5 0.94), with a regression coef-
ficient consistent with the Canadian study.
Additional Evidence from Perinatal
Mortality Surveillance
In order to provide an independent data source and
measure of the effect of folic acid fortification, an existing
perinatal mortality surveillance system was also utilized,
the Perinatal Problem Identification Programme (PPIP).
Pattinson et al. (2005) aimed to identify the common
causes of death and associated factors that could be
addressed to reduce the perinatal mortality rate. Basic
perinatal birth data and causes of death up to 7 days of
age were recorded. A category of NTDs was included in
the classification in anticipation of folic acid fortification.
All perinatal deaths (stillbirths and neonatal deaths of
500 g or more) were recorded at 164 sentinel health care
facilities spread throughout urban and rural areas of
South Africa.
Table 3 shows a comparison of prefortification (2001–
2003) and postfortification (2005–2006) perinatal mortality
rates from NTDs. There was a significant decline of
65.9% in NTD perinatal mortality, from 0.42 to 0.14 per
1,00 births (RR 5 0.34; 95% CI: 0.25–0.47; p < .001). As a
control, the perinatal mortality rate of hydrocephalus,
unrelated to NTDs, did not change significantly (RR 5
0.92; 95% CI: 0.54–1.57; p 5 .7732).
Further Evidence from National Infant
Mortality Statistics
It is also possible to detect a reduction in NTD mortal-
ity following fortification in national mortality statistics
produced by Statistics South Africa (2007). Unit records
of all registered deaths under 1 year of age for the period
1998 to 2005, coded to ICD-10 at the three character level,
were analyzed annually. Because birth registration is
incomplete, and the completeness of routine death regis-
tration is not precisely known and may vary from year to
year, the proportion of NTDs to all other congenital
anomalies was calculated, rather than an absolute rate.
This data give us a longer prefortification baseline than
the two sources of data presented earlier in this article
(Fig 1). Between 1998 and 2003 there was no significant
trend in the proportion of NTDs (v2 5 1.36; p 5 .244),
while from 2003 to 2005 there was a strong downward
trend (v2 5 11.02; p < .001). In 2003 the proportion was
12.37% (95% CI: 10.25–14.75) and in 2005 it was 7.57%
(5.91–9.52). The decline of 38.8% in the proportion is sig-
nificant (p 5 .0008).
Population Cost Benefit of Folic Acid Fortification
in South Africa
We estimated the cost benefit of fortification by com-
paring the direct cost of fortification against the direct
cost of minimal medical intervention in the short term.
The cost of folic acid at 2% of the fortification premix is
R1.4 million (1 US$ 7 ZAR) per annum. In South Africa
medical tariffs vary considerably amongst the public and
private sector medical insurance companies, where 85%
of the population do not have the benefits of private
health insurance (Council for Medical Schemes, 2006).
The costing in this study was based on the Uniform
Patient Fee Schedule Uniform Professional Fee Structure
of the Department of Health (2006), which is used in pro-
vincial and government hospitals. Uniform Patient Fee
Schedule Uniform Professional Fee Structure is consider-
ably lower than private sector rates. It must be noted that
although these procedures are listed, not all children
born with these conditions will have the benefit of this
quality of health care.
Table 4 shows the minimal medical interventions and
estimated costs for appropriate care during the first year
of life. Typically, as an example, the total cost for treat-
Table 2
Comparison of Pre- and Postfortification Rates of Specific NTDs (Anencephaly and Spina Bifida) and Oro-Facial Clefts
Condition
Prefortification Postfortification Percentage decline
Cases Rate/1,000 Cases Rate/1,000
RR
(95% CI)
Anencephaly 33 0.41 17 0.37 10.9%
RR 5 0.89
(0.50–1.60)
Spina bifida 74 0.93 25 0.54 41.6%
RR 5 0.58
(0.37–0.92)
Oro-facial clefts 33 0.41 18 0.39 5.7%
RR 5 0.94
(0.53–1.68)
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ment in the first year of life for a newborn with myelo-
meningocoele is about R70,000.
It is therefore not unreasonable to conservatively esti-
mate the average cost of treatment of R100,000 per case
during the first 3 years of life of a cohort. South Africa
has a prefortification spina bifida rate of 0.93/1,000 and
a birth population of 1.05 million. There are therefore
approximately 976 cases of spina bifida per year. With a
41.6% reduction 406 cases are averted per annum,
resulting in a saving of R40.6 million per annum. This
gives a cost benefit ratio of approximately 30 to 1 for
folate fortification as a cost effective primary health care
intervention. If the true national prevalence rate for
NTDs is greater than that observed in our hospital
based surveillance system, the cost benefit ratio will be
greater.
DISCUSSION
This study has demonstrated a significant decline in
the prevalence of NTDs following folic acid fortification
in South Africa. This is the first time that data on the
result of folate fortification have been presented for a
predominantly African population. In addition to the
main sentinel site surveillance, the PPIP surveillance sys-
tem, an independent perinatal mortality data source, also
shows a significant decline in perinatal deaths from
NTDs, as did a third independent data set on cause spe-
cific infant mortality from national civil registration of
deaths. All three systems showed a decline in NTD com-
mencing at the time when fortification was introduced.
In countries where it is not feasible to institute morbidity
surveillance, national death registration (Setel et al., 2007)
or perinatal mortality surveillance may provide a suitable
alternative.
The decrease in NTD rate postfortification is consistent
with decreases observed in other countries that have for-
tified their food supplies. In Chile (Hertrampf et al., 2004;
Jorge, 2005), Costa Rica (Chen et al., 2004), Canada (De
Wals et al., 2007), and specifically Nova Scotia (Persad
et al., 2002), where mandatory fortification of basic food-
stuffs has been implemented, more than 30% reduction
in NTDs was noted. In the USA, the decline in spina
bifida in association with fortification has been consis-
tently greater than the decline in anencephaly (Mathews
et al., 2002; Williams et al., 2005). A similar relative
decline in spina bifida and anencephaly has been repli-
cated in this study. There is no substantial prenatal inter-
vention for NTDs in South Africa.
This study showed that Eastern Cape Province had the
highest prefortification NTD rates and also had the high-
est decline of 40.1%. It is also noted that in a supplemen-
tation study in China there was a greater decline in the
north where rates were higher as compared to the south
with its lower rates (Berry et al., 1999).
This study also shows there was no significant reduc-
tion in oro-facial clefts, a decline of 5.7% being observed.
Recent studies in Western Australia (Bower et al., 2006)
and in Canada (Ray et al., 2003; Botto et al., 2006) also
showed no evidence of folate being an important factor
in the prevention of birth defects other than NTDs.
An earlier mainly urban based surveillance reported
annually to the International Clearinghouse for Birth
Defects Surveillance and Research (2005) showed no sig-
Table 3
Comparison of Pre- and Postfortification Perinatal Mortality Rates for NTDs and Hydrocephalus from the PPIP
Surveillance System
Perinatal condition
Prefortification 2001–2003 Postfortification 2005–2006 Percentage decline
Total births: 486,950 Total births: 321,711 RR
Deaths Rate/1,000 Deaths Rate/1,000 (95% CI)
NTD 204 0.419 46 0.143 65.9%
RR 5 0.34
(0.25–0.47)
Hydrocephalus 36 0.074 22 0.068 7.5%
RR 5 0.92
(0.54–1.57)
Figure 1. Proportion of NTD deaths to all other congenital anomalies, <1 year, South Africa 1998–2005.
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nificant trend for NTDs over the period 1994–2003, and
infant mortality data also showed no trend for NTDs
from 1998–2003.
The surveillance of NTDs, both before and after fortifi-
cation, took place in an environment of one of the highest
HIV infection rates in the world. The average HIV preva-
lence rate among pregnant women in South Africa was
given by the Department of Health (2005) as 27.9% in
2003 and 29.5% in 2004, with an estimated 5 million indi-
viduals of both sexes infected with HIV (Dorrington
et al., 2005). Although some antiretroviral therapy (ARV)
may increase the risk for NTDs (De Santis et al., 2002),
the rollout of ARV was slow (Stewart and Loveday,
2005), and by April 2005, only about 50,000 persons were
on treatment with ARVs, so this is unlikely to have influ-
enced the findings.
Although it is difficult to compare cost benefits of forti-
fication in different countries, the cost benefit ratio in
averting NTDs was approximately 30 to 1 in this study,
in the United States 40 to 1 (Grosse et al., 2005), and in
Chile 10 to 1 (Llanos et al., 2006).
CONCLUSION
This study shows a significant decline in the preva-
lence of NTDs following folic acid fortification in South
Africa. The decrease in NTD rates postfortification is con-
sistent with decreases observed in other countries that
have fortified their food supplies. This is the first time
this has been observed in a predominantly African popu-
lation. The economic benefit flowing from the prevention
of NTDs greatly exceeds the costs of implementing folic
acid fortification, as shown in other studies around the
world, and is an extremely cost effective primary health
care intervention.
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